Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20898158 | 0.80 | TSHR (0.97) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4578170 | 0.78 | USP2 (0.83) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3577214 | 0.78 | TSHR (0.55) | TSHRKDM4EALDH1A1 | |
| SCHEMBL11736541 | 0.77 | TSHR (0.90) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL15884439 | 0.76 | HRH3 (0.54) | TSHRUSP2MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL6857854 | 0.76 | AAK1 (0.40) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4578593 | 0.76 | L3MBTL1 (1.00) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL16392430 | 0.75 | L3MBTL1 (0.74) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL24378058 | 0.74 | PKM (0.84) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL8356145 | 0.74 | PKM (0.84) | TSHRUSP2MAPK1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | TSHR 3945/4885USP2 2356/4885MAPK1 40/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | TSHR 3945/4885USP2 2356/4885MAPK1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.